Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25647381 | 1.00 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31338167 | 0.89 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25647387 | 0.86 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31076625 | 0.86 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31338131 | 0.86 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25226548 | 0.85 | IKZF2 (0.65) | CRBNIKZF3IKZF2 | |
| SCHEMBL25227389 | 0.85 | CRBN (0.63) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31338059 | 0.85 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31338139 | 0.85 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31338147 | 0.85 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745137-A1 | GLUTARIMIDE ISOINDOLINONE SKELETON-BASED COMPOUND | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025016359-A1 | GLUTARIMIDE ISOINDOLINONE SKELETON-BASED COMPOUND | 标新生物医药科技(上海)有限公司 | 2025-01-23 | — | — | WO | claimed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| EP-4745137-A1 | GLUTARIMIDE ISOINDOLINONE SKELETON-BASED COMPOUND | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025016359-A1 | GLUTARIMIDE ISOINDOLINONE SKELETON-BASED COMPOUND | 标新生物医药科技(上海)有限公司 | 2025-01-23 | — | — | WO | disclosed |